Key facts
- It has raised $1.4M; the latest was Early Stage VC ($1.4M) in Dec 2025.
- Notable investors include Oriental Fortune Capital, Ningbo Angel Capital Guiding Fund, Chengshu Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Changfeng Biology
- ·The full record, as it builds
Funding rounds
No funding rounds for Changfeng Biology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Changfeng Biology
Developer of biomedical material transformation technologies, focused on addressing clinical challenges across multiple medical disciplines. The company's offerings include advanced biomaterials for applications in aesthetics, dentistry, orthopedics, and oncology, thereby designed to improve treatment outcomes through continued innovation, clinical research, and scalable commercialization.
- Sector
- Healthcare
- HQ
- Ningbo, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Changfeng Biology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Changfeng Biology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Changfeng Biology in its N-PORT filings yet. We sweep new filings monthly.